We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.66 | -9.91% | 6.00 | 6.02 | 6.98 | 6.00 | 6.00 | 6.00 | 33,263 | 08:16:11 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.76 | 13.41M |
From Apr 2019 to Apr 2024
TIDMSNG
RNS Number : 5139L
Synairgen plc
30 April 2020
Press release
Synairgen plc
('Synairgen' or the 'Company')
Approval received to extend SG016 clinical study of SNG001 in COVID-19 to initiate patients in the home environment
Southampton, UK - 30 April 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that it has received approvals to extend the SG016 trial to patients with SARS-CoV-2 in the home environment. The objective is to initiate dosing with SNG001 (or placebo) earlier in the infection cycle, and before severe lower respiratory tract symptoms have developed. In due course, details of the design, implementation and timing of this novel study will be disclosed more fully.
The treatment of patients in the hospital setting in the SG016 study is progressing well, with more than 75 patients out of the target 100 now dosed with Synairgen's wholly-owned drug SNG001 or placebo. Results from this part of the study are still expected in June 2020.
For further enquiries, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Finance Director
Tel: + 44 (0) 23 8051 2800
finnCap
Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)
Alice Lane, Manasa Patil (ECM)
Tel: + 44 (0) 20 7220 0500
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott, Sue Stuart, Olivia Manser
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
Notes for Editors
About Synairgen
Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.
Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
MSCURRARRSUSOAR
(END) Dow Jones Newswires
April 30, 2020 07:09 ET (11:09 GMT)
1 Year Synairgen Chart |
1 Month Synairgen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
